Clinical Trial Update: Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study [Phase 2]

View source ↗

Summary

An open-label Phase II trial evaluating abatacept for inflammatory arthritis in patients with primary or secondary Sjögren's syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Arthritis
• Rheumatoid Arthritis
• Sjögren Syndrome

Drugs mentioned

• Abatacept (abatacept)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome | Phase 2 | Status: WITHDRAWN